(Q34159870)

31 July 2017

1 reference

title

The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? (English)

1 reference

31 July 2017

0 references

1 reference

Jeffrey Perl

1

1 reference

31 July 2017

Sharon J Nessim

series ordinal

2

1 reference

31 July 2017

Joanne M Bargman

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

19 January 2011

1 reference

31 July 2017

1 reference

31 July 2017

79

1 reference

31 July 2017

814-824

1 reference

31 July 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.515

31 July 2017

0 references

cites work

Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

A six-year comparison of patient and technique survivals in CAPD and HD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Impact of terminal heat sterilization on the quality of peritoneal dialysis solutions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Effect of pH and glucose on cultured human peritoneal mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Changes in peritoneal mesothelial cells phenotype after chronic exposure to glucose or N-acetylglucosamine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Toxicity of osmotic solutes on human mesothelial cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Laminin alterations after in vitro nonenzymatic glycosylation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

In vitro formation of advanced glycation end products in peritoneal dialysis fluid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer-effects on human mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Peritoneal leukocyte survival and respiratory burst responses in patients treated with a low glucose degradation and high pH peritoneal dialysis fluid.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

CA 125 secretion by peritoneal mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Longitudinal follow-up of CA125 in peritoneal effluent

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Improved Acidosis Correction and Recovery of Mesothelial Cell Mass with Neutral-pH Bicarbonate Dialysis Solution among Children Undergoing Automated Peritoneal Dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Vascular endothelial growth factor: biology and therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Growth factors VEGF and TGF-beta1 in peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Myofibroblastic conversion of mesothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Advanced glycation end products: sparking the development of diabetic vascular injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Advanced glycosylation end products in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Advanced glycation end products and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Impact of new dialysis solutions on peritonitis rates

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Impact of age on peritonitis risk in peritoneal dialysis patients: an era effect

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Mortality and technique failure in patients starting chronic peritoneal dialysis: Results of the Netherlands Cooperative Study on the Adequacy of Dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

The importance of residual kidney function for patients on dialysis: a critical review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Role of advanced glycation end products in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.515

7 January 2021

Identifiers

DOI

10.1038/KI.2010.515

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference